They have Ardelyx Assist to try and help those who dont have commercial insurance .....but dont think they make any $ off it . Ibsrela is going great and getting $25m rev from only 10% of the dialysis population ...Xphozah ..is impressive . So Mott buying all those times worked out . Gr8 hedge for UNCY . If ARDX is ever able to get CMS to change their stance on the new binders in the dialysis bundle ...ie extend reimbursement beyond the first 2 yrs in TDAPA ....would be a huge win for ARDX and eventually UNCY . Their case vs CMS is under appeal ...hearing later this yr Kiwi